Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of New Encorafenib Formulations and PPI Effect
NCT05446142Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of encorafenib in melanoma, colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-Time Profile From Time Zero to Extrapolated Infinite Time, Maximum Observed Plasma Concentration and 1 more. Started Jul 2022; status: completed.
02
Drugs
encorafenib
03
Conditions
melanomacolorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05446142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05446142.